Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis

Blood

Volumn 107, Issue 9, 2006, Pages 3738-3744

  Pennell, Dudley J ^a   Berdoukas, Vasili ^b   Karagiorga, Markissia ^b   Ladis, Vasili ^b   Piga, Antonio ^b   Aessopos, Athanassios ^b   Gotsis, Efstathios D ^b   Tanner, Mark A ^b   Smith, Gill C ^b   Westwood, Mark A ^b   Wonke, Beatrix ^b   Galanello, Renzo ^b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADULT; AGRANULOCYTOSIS; ARTHRALGIA; ARTICLE; BETA THALASSEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VOLUME; HUMAN; INJECTION SITE REACTION; JOINT SWELLING; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MYOCARDIAL DISEASE; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDEROSIS; VITAL SIGN; VOMITING;

EID: 33646387405     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-07-2948     Document Type: Article

References (53)

1. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;2:27-30.
2. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331: 574-578.
3. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 1998;850:227-233.
4. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187-1193.
5. Anderson LJ, Holden S, Davies B, et al. Cardiovascular T2* (T2 star) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171-2179.
6. Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E. Thalassemia. In: Hematology. Washington, DC: American Society of Hematology; 2004:14-34.
7. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103:1934-1936.
8. Westwood MA, Wonke B, Maceira AM, et al. Left ventricular diastolic function compared with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major. J Magn Reson Imaging. 2005;22:229-233.
9. Westwood MA, Anderson LJ, Tanner MA, Pennell DJ. The relationship between myocardial iron deposition and left ventricular dysfunction in thalassemia using cardiovascular magnetic resonance [abstract]. J Cardiovasc Magn Reson. 2005;7:46-47. Abstract 153.
10. Tanner MA, Porter JB, Westwood MA, et al. Myocardial T2* in patients with cardiac failure secondary to iron overload [abstract]. Blood. 2005;106: 406. Abstract 3838.
11. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004;127:348-355.
12. Kirk P, Pennell DJ. Myocardial T2* is not affected by the structural effects of myocardial fibrosis, ageing or impaired left ventricular function [abstract]. Blood. 2005;106:478a. Abstract 1675.
13. Westwood M, Anderson LJ, Firmin DN, et al. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging. 2003;18:33-39.
14. Westwood M, Anderson LJ, Firmin DN, et al. Interscanner reproducibility of cardiovascular magnetic resonance in the early diagnosis of myocardial iron overload. J Magn Reson Imaging. 2003; 18:616-620.
15. Westwood MA, Firmin DN, Gildo M, et al. Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemia. Int J Cardiovasc Imaging. 2005;21:531-538.
16. Wood JC, Enriquez CM, Powell A, et al. Single echo versus multiple echo cardiac T2* estimates for cardiac iron estimation in iron overload [abstract]. J Cardiovasc Magn Reson. 2005;7:97. Abstract 309.
17. Kirk P, Anderson LJ, Tanner MA, et al. Intersite validation of a single breath-hold T2* MR technique for heart and liver iron measurement [abstract]. Blood. 2005;106:38b. Abstract 3830.
18. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106:1460-1465.
19. Wood JC, Otto-Duessel M, Aguilar M, et al. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation. 2005;112:535-543.
20. Pennell DJ, Anderson LJ, Kirk P, et al. Calibration of myocardial T2* values in post-mortem hearts [abstract]. Blood. 2005;106:40b. Abstract 3837.
21. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron levels and ventricular function in beta thalassemia. Lancet. 2002;360:516-520.
22. Ghugre NR, Enriquez CM, Coates TD, Nelson MD, Wood JC. Improved R2* measurements in myocardial iron overload. J Magn Reson Imaging. 2006;23:9-16.
23. Pennell DJ. Cardiovascular magnetic resonance. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, PA: Elsevier Saunders; 2005:335-353.
24. Grothues F, Smith GC, Moon JC, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol. 2002;90:29-34.
25. Brittenham GM, Farrell DE, Harris JW, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med. 1982;307:1671-1675.
26. Fung EB, Longo F, Fischer R, et al. Comparison of liver iron concentration measured by the SQUID biosusceptometers at Hamburg, Torino and Oakland in patients with thalassemia and sickle cell disease [abstract]. Blood. 2005;106:8b. Abstract 3721.
27. Porter JB. Practical management of iron overload. Br J Haematol. 2001;115:239-252.
28. Lorenz CH, Walker ES, Morgan VL, Klein SS, Graham TP Jr. Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging. J Cardiovasc Magn Reson. 1999;1:7-21.
29. Aessopos A, Farmakis D, Hatziliami A, et al. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol. 2004;73:359-366.
30. Westwood MA, Anderson LJ, Maceira AM, et al. Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron [abstract]. Blood. 2005;106:760a. Abstract 2707.
31. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood. 2004;104:263-269.
32. The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med. 1983;309:331-336.
33. Parameshwar J, Keegan J, Sparrow J, Sutton GC, Poole-Wilson PA. Predictors of prognosis in severe chronic heart failure. Am Heart J. 1992; 123:421-426.
34. The CONSENSUS study group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
35. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334: 1349-1355.
36. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76:44-51.
37. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med. 1997;336:1350-1355.
38. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure: SOLVD Investigators. Circulation. 1992; 86:431-438.
39. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88:489-496.
40. Wolfe L, Olivieri N, Sallan D, et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med. 1985;312:1600-1603.
41. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331:567-573.
42. Giardina PJ, Ehlers KH, Engle MA, Grady RW, Hilgartner MW. The effect of subcutaneous deferoxamine on the cardiac profile of thalassemia major: a five-year study. Ann N Y Acad Sci. 1985; 445:282-292.
43. Porter JB. Development of Primary Hepatocyte Cultures for the Preclinical Evaluation of Iron Chelators [master's thesis]. Cambridge, United Kingdom: University of Cambridge; 1999.
44. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. In: Hematology. Washington, DC: American Society of Hematology; 2001:47-61.
45. de Franceschi L, Shalev O, Piga A, et al. Deferiprone therapy in homozygous human betathalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity. J Lab Clin Med. 1999;133:64-69.
46. Shalev O, Repka T, Goldfarb A, et al. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood. 1995;86: 2008-2013.
47. Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in ironloaded rat heart cells in culture. J Lab Clin Med. 2001;138:130-138.
48. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003;121:187-189.
49. Tanner MA, Westwood MA, Galanello R, Pennell DJ. Baseline findings of a CMR driven randomized controlled trial of iron chelation therapy in thalassemia major [abstract]. J Cardiovasc Magn Reson. 2005;7:31-32. Abstract 133.
50. Maggio A, D'Amico G, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis. 2002;28:196-208.
51. Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH. Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan. Eur J Haematol. 2003; 70:392-397.
52. Galia M, Midiri M, Bartolotta V, et al. Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study. Hemoglobin. 2003;27:63-76.
53. Olivieri NF, Brittenham GM, Armstrong SA, et al. First prospective randomized trial of the iron chelators deferiprone (L1) and deferoxamine [abstract]. Blood. 1995;86:249.